ADC Therapeutics hires Genmab VP
01.08.2012 - Antibody drug-conjugates specialist ADC Therapeutics Sarl has named the former Genmab Vice President Dr Patrick van Berkel as its Senior VP Research & Development.
Van Berkel brings in more than 20 years of experience in the biotech industry, in particular in developing antibody-based drugs. He served with Genmab for more than nine years in different divisions. Prior to Genmab, Dr van Berkel worked for both Crucell and Pharming Technologies. He authors nine antibody patents and has published more than 30 scientific papers during his industry career. Van Berkel predicts an „explosion in ADC therapies in the coming decade“.http://www.european-biotechnology-news.com/people/bio-people/2012-2/patrick-van-berkel.html